MicroStrategy recently announced its 2nd quarter earnings for 2022, which turned the heads of thousands of people around the world. According to the report, the company bought a digital impairment charge that was estimated at 917.8 million dollars. An impairment charge is a sign that an asset's recoverable value is in decline. But does this impairment charge have a meaningful impact on the company's inherent value? Will MicroStrategy's share price come tumbling down? Or is the stock still a decent buy? Before we get to the answer to these questions, we must discuss the company's background and its performance on the stock market first.
MicroStrategy's background and overview:
MicroStrategy is one of the biggest names in the business intelligence industry, if not THE most. For a company to become successful, it has to have a seamless data analytics platform, with the help of which it can allow its users to present with customised visualisations and personalised dashboards. Moreover, that platform should help connect the users to the data sources such as information repositories, cloud databases, physical access systems, warehouses, and web-based applications. MicroStrategy is not just that platform; it is much more than that.
MicroStrategy has different tools and capabilities under its belt, which help its users schedule an automated personalised reports delivery through security roles and user preferences. The company's top-notch, open, and modern platform enables you to build high-quality intelligence applications, allows users to utilise data discovery, and delivers the required content to customers, partners, or employees within a matter of minutes or even seconds. To improve communication within your teams and departments, MicroStrategy's platforms will enhance collaboration between employees with innovative features like live messaging. Additionally, the company's tools also serve the purpose of protecting your important and sensitive data by security-by-design and automatic localisation.
Among the company's products, these deserve a special mention:
- MicroStrategy Dossier: If you want to include innovative dashboard layouts in your presentations, make important data stories using business intelligence applications, try self-service data discovery, and want to make interactive, unique analytics content almost instantaneously, Dossier is just what you were looking for. The product has a great drag-and-drop interface with several intuitive formatting options.
- MicroStrategy Library: Among many requisites, an essential requirement for a company to become successful is for it to make decisions based on up-to-date data. Library helps keep your data at the centre of your choices. With the help of Library, users can create personalised analytics portals that they can share with any of their fellow team members. This advantage provides an edge to the team while making critical decisions.
- HyperIntelligence: HyperIntelligence is another MicroStrategy product that assists its users in making better decisions by delivering relevant data into daily workflows. Using this tool, you can scan applications, emails, and websites for specific keywords and, by doing so, deliver an augmented experience. Moreover, each of your employees or fellow team members can securely get zero-click insights without doing any coding.
MicroStrategy's success stories:
If these products do not spell “MicroStrategy's success” for you, there are numerous customer success stories in store for you. Most of us are aware of the fact that Pfizer is a giant in the healthcare sector and one of the pharmaceutical leaders in the world, especially due to the fact that the vaccine developed by Pfizer has prevented millions of people from getting infected by the coronavirus and is recognised at a global level.
Such a company would require a competent, working business intelligence platform that would not only arrange and organise the data but also redistribute it internally to enable analytics, data curation, linking, tagging, and searching.
According to Pfizer's director of Data & Analytics Tools, the company lacked a tool to deliver important business information to reps, no immediate updates on business performance, and no knowledge about employee productivity. Although the company was using the services of Tableau, it could not get a precise insight into daily performance and activity. MicroStrategy not only helped Pfizer boost its sales productivity, but also enabled Pfizer's employees to be equipped with top-tier technology that enhanced their individual performances.
Usually, organisations that are as huge as Pfizer manage their cloud and database. Pfizer, on the other hand, chose MicroStrategy's cloud instead of going for a do-it-yourself approach and benefited from it immensely. MicroStrategy's cloud services provided a reliable solution to Pfizer's Data & Analytics team and assisted the employees in overcoming issues and focusing on per-day delivery.
Other than Pfizer, multichannel retailer EziBuy has made the most of the company's HyperIntelligence, while Microplastics has successfully accelerated supply chain decisions by using MicroStrategy's embedded intelligence.
Is MSTR a buy now:
MicroStrategy was listed on the NASDAQ on the 11th of July 1998, under the ticker MSTR, so it is definitely not a young company. At its IPO, the company traded at a mere 12 dollars a share. The company raised almost 48 million dollars on the first day of being listed on the stock market. The share price skyrocketed in 2000. It reached an all-time high of almost 1400 dollars per share in February, but unfortunately, within a year, it fell back to around 25 dollars. Over time, it rose again, but this time, the rise was slow and steady. It crossed the 100-dollar mark in 2010 and continued to rise steadily, although it would experience a few drops occasionally. In 2020, the company and shareholders alike made a lot of money when the share price spiked to 400 dollars. In February 2021, the company traded at 750 dollars. But sadly, as had been the company's case over the years, MSTR's success was short-lived.
Currently, the company trades at 245 dollars. If you are a frequent investor, you might be aware of the Zacks Rank and VGM Score. If not, these are some valuation metrics that can help you make an educated guess about whether a certain stock is a good buy or not. MSTR has a Zacks Rank 4 and a VGM Score of 4, but several financial experts believe that the company might prove to be a decent investment in the long run, with a prediction of a yearly gain of 57 percent.
The information in this article is well-researched and factual. Still, it contains opinions also, and IT IS NOT FINANCIAL ADVICE and should not be interpreted as such, do not make any financial decisions based on the information in this article; we are not financial advisors. We are journalists. You should always consult with a professional before making any investment decisions.